A monoclonal antibody directed against CD52, a antigen (or marker) found on both B and T lymphocytes. The drug is used most often to treat chronic lymphocytic leukemia and has been used in the treatment of advanced CTCL. (Campath® is the brand name for Alemtuzumab).